An uncommon association of antiphospholipid syndrome, selective IgA deficiency and resistant-to-treatment relapsing polychondritis: efficacy of infliximab.

Abstract

Autoimmune complications in the context of primary immunodeficiency diseases represent a well-known phenomenon, and this is widely recognized also for Selective Immunoglobulin A deficiency (IgAD), the most common primary antibody deficiency (PAD). Relapsing polychondritis (RP) is a rare immune-mediated, difficult to treat, disorder in which the cartilaginous tissues are the target for inflammation and damage. Ocular inflammatory manifestations in RP are frequent and often sight-threatening. Antiphospholipid syndrome (APS) is an acquired prothrombotic state related to circulating autoantibodies against phospholipids and/or their cofactors. Rare reports of APS associated to RP, PAD and APS or PAD and RP are available.

• Authors: D Firinu, A Frau, M Pisanu, M M Lorai, R Meleddu, F Musu, P E Manconi, S R Del Giacco
• Journal: Journal of biological regulators and homeostatic agents (J Biol Regul Homeost Agents) 2012 Oct-Dec Vol. 26 Issue 4 Pg. 785-8 ISSN: 0393-974X [Print] Italy
• PMID: 23241130 (Publication Type: Case Reports, Letter)

Chemical References

• Antibodies, Monoclonal
• Tumor Necrosis Factor-alpha
• Infliximab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antiphospholipid Syndrome (complications)
• Female
• Humans
• IgA Deficiency (complications)
• Infliximab
• Middle Aged
• Polychondritis, Relapsing (drug therapy)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)